PL2643698T3 - Biomarkery do przewidywania skuteczności immunoterapii raka - Google Patents

Biomarkery do przewidywania skuteczności immunoterapii raka

Info

Publication number
PL2643698T3
PL2643698T3 PL11788121.9T PL11788121T PL2643698T3 PL 2643698 T3 PL2643698 T3 PL 2643698T3 PL 11788121 T PL11788121 T PL 11788121T PL 2643698 T3 PL2643698 T3 PL 2643698T3
Authority
PL
Poland
Prior art keywords
biomarkers
predict
effectiveness
cancer immunotherapy
immunotherapy
Prior art date
Application number
PL11788121.9T
Other languages
English (en)
Inventor
Toni Weinschenk
Harpreet Singh
Jens Fritsche
Andrea Mahr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2643698T3 publication Critical patent/PL2643698T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
PL11788121.9T 2010-11-24 2011-11-22 Biomarkery do przewidywania skuteczności immunoterapii raka PL2643698T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41698110P 2010-11-24 2010-11-24
GBGB1021289.2A GB201021289D0 (en) 2010-12-15 2010-12-15 Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US42365210P 2010-12-16 2010-12-16

Publications (1)

Publication Number Publication Date
PL2643698T3 true PL2643698T3 (pl) 2016-12-30

Family

ID=43567254

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11788121.9T PL2643698T3 (pl) 2010-11-24 2011-11-22 Biomarkery do przewidywania skuteczności immunoterapii raka

Country Status (17)

Country Link
US (2) US8669063B2 (pl)
EP (1) EP2643698B1 (pl)
JP (1) JP6005051B2 (pl)
KR (1) KR20130119453A (pl)
CN (1) CN103384827B (pl)
AU (1) AU2011333819A1 (pl)
BR (1) BR112013012820A2 (pl)
CA (1) CA2818738A1 (pl)
EA (1) EA201390762A1 (pl)
ES (1) ES2592957T3 (pl)
GB (1) GB201021289D0 (pl)
HU (1) HUE030005T2 (pl)
MX (1) MX341734B (pl)
NZ (1) NZ609712A (pl)
PL (1) PL2643698T3 (pl)
SG (1) SG190698A1 (pl)
WO (1) WO2012069462A1 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172211B1 (en) 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
US9026531B2 (en) * 2012-04-17 2015-05-05 Cerner Innovation, Inc. Associating multiple data sources into a web-accessible framework
WO2014003853A1 (en) 2012-06-26 2014-01-03 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
CN103048453B (zh) * 2012-12-18 2014-11-26 苏州浩欧博生物医药有限公司 一种糖类抗原ca19-9的纳米磁微粒化学发光测定试剂盒及其制备方法和检测方法
JP6645703B2 (ja) * 2013-11-07 2020-02-14 メディアル リサーチ リミテッド 肺癌のリスクを評価する方法およびシステム
EP2942629A1 (en) * 2014-05-08 2015-11-11 Universität Würzburg Predictive markers for successful cancer immunotherapy
GB201505585D0 (en) * 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
WO2017008046A1 (en) * 2015-07-08 2017-01-12 Children's Hospital Medical Center Loss of transcriptional fidelity leads to immunotherapy resistance in cancers
CN112710723B (zh) * 2015-07-13 2024-11-12 佰欧迪塞克斯公司 受益于pd-1抗体药物的肺癌患者的预测性测试和分类器开发方法
BR112018012374A2 (pt) 2015-12-16 2018-12-04 Gritstone Oncology, Inc. identificação, fabricação e uso de neoantígeno
WO2017136139A1 (en) 2016-02-01 2017-08-10 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (il2) therapy
CN105624110A (zh) * 2016-02-29 2016-06-01 时宏珍 Hla-a0201限制性抗psa抗原特异性ctl的制备方法
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
WO2017194556A1 (en) * 2016-05-09 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for classifying patients with a solid cancer
WO2018039452A1 (en) * 2016-08-24 2018-03-01 The Wistar Institute Of Anatomy And Biology Methods of treating cancers with chemotherapy with reduced toxicity
CN106198987A (zh) * 2016-08-31 2016-12-07 辽宁迈迪生物科技股份有限公司 一种用于评价肿瘤免疫细胞疗法的检测标记物及其检测方法和应用
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
CN116884477A (zh) * 2017-01-05 2023-10-13 佰欧迪塞克斯公司 用于鉴定总体不良预后亚组中持久受益于免疫疗法的癌症患者的方法
US11747345B2 (en) 2017-02-21 2023-09-05 The Board Of Regents Of The University Of Texas System Prediction and treatment of immunotherapeutic toxicity
US10699007B2 (en) * 2017-03-13 2020-06-30 Oracle International Corporation Hybrid univariate/multivariate prognostic-surveillance technique
CN110023760B (zh) * 2017-06-02 2023-04-14 李宗均 一种利用结直肠癌患者和正常人外周血内免疫细胞的分布差异评估免疫力并提供结直肠癌发病情况信息的诊断工具
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
IL274799B2 (en) 2017-11-22 2025-05-01 Gritstone Bio Inc Reducing junction epitope presentation for neoantigens
WO2019190732A1 (en) 2018-03-29 2019-10-03 Biodesix, Inc. Apparatus and method for identification of primary immune resistance in cancer patients
WO2019195823A1 (en) * 2018-04-06 2019-10-10 The Board Of Regents Of The University Of Texas System Prediction and treatment of immunotherapeutic toxicity
CN108624650B (zh) * 2018-05-14 2022-04-29 乐普（北京）医疗器械股份有限公司 判断实体瘤是否适合免疫治疗的方法和检测试剂盒
CN110885886B (zh) * 2018-09-07 2023-04-07 华中科技大学同济医学院附属协和医院 一种胶质母细胞瘤鉴别诊断及胶质瘤生存预后的分型方法
KR102159538B1 (ko) * 2019-01-11 2020-09-24 충남대학교 산학협력단 폐암 환자의 면역항암제에 대한 치료 반응성 예측용 il-6 마커 및 이의 용도
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning
US20220165362A1 (en) * 2019-03-28 2022-05-26 Hoffmann-La Roche Inc. Cancer prognosis
CN111257563B (zh) * 2020-01-22 2022-08-23 广州泛恩生物科技有限公司 Cxcl13检测剂在制备预测免疫治疗效果的试剂盒中的用途
IL299323A (en) * 2020-06-21 2023-02-01 Oncohost Ltd Repository signatures for predicting response to immunotherapy
WO2022006514A1 (en) * 2020-07-02 2022-01-06 Gopath Laboratories Llc Immune profiling and methods of using same to predict responsiveness to an immunotherapy and treat cancer
CN115777065A (zh) * 2020-07-10 2023-03-10 积水医疗株式会社 含有tarc的组合物和用于改善tarc的储存稳定性的方法
CN115777066A (zh) * 2020-07-10 2023-03-10 积水医疗株式会社 含有tarc的组合物和改善tarc储存稳定性的方法
CN113219173A (zh) * 2021-05-11 2021-08-06 中南大学湘雅医院 Sh2b1在肺癌诊断中的应用
CN113462776B (zh) * 2021-06-25 2023-03-28 复旦大学附属肿瘤医院 m6A修饰相关联合基因组在预测肾透明细胞癌患者免疫治疗疗效中的应用
CN115058440B (zh) * 2022-06-08 2023-08-15 郑州轻工业大学 催化合成天然蔗糖酯的工程菌及其构建方法和应用
CN115612737A (zh) * 2022-08-03 2023-01-17 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种胃癌免疫治疗疗效预测和预后评估的方法及其应用
CN118072954A (zh) * 2024-02-06 2024-05-24 江南大学附属医院 一种基于trp评分系统的胃癌免疫治疗反应预测方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
JP3490893B2 (ja) * 1998-06-02 2004-01-26 富士レビオ株式会社 胃癌の診断方法
WO2005098446A2 (en) * 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
RU2008121754A (ru) * 2005-11-02 2009-12-20 БАЙЕР ХЕЛСКЕР ЛЛСи (US) Способы прогнозирования и предсказания рака и мониторинг терапии раковых заболеваний
US20090035801A1 (en) * 2005-12-27 2009-02-05 Power3 Medical Products, Inc. Twelve (12) protein biomarkers for diagnosis and early detection of breast cancer
EP3255432B1 (en) * 2006-04-24 2019-01-23 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
AT504231A1 (de) * 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
CA2817054C (en) * 2007-07-27 2017-02-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
EP2080812A1 (en) * 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
EP2105740A1 (en) 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Biomarkers for monitoring or predicting the treatment of cancer
US20110166838A1 (en) 2008-06-16 2011-07-07 Sividon Diagnostics Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
WO2010076322A1 (en) 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer
US20100240546A1 (en) * 2009-03-20 2010-09-23 Samuel Chun Lap Lo Use of biomarkers for the diagnosis and prognosis of lung cancer

Also Published As

Publication number Publication date
US20120128702A1 (en) 2012-05-24
US20140234347A1 (en) 2014-08-21
US8669063B2 (en) 2014-03-11
EA201390762A1 (ru) 2013-09-30
BR112013012820A2 (pt) 2017-05-09
MX341734B (es) 2016-08-31
NZ609712A (en) 2015-05-29
AU2011333819A1 (en) 2013-05-23
SG190698A1 (en) 2013-07-31
ES2592957T3 (es) 2016-12-02
EP2643698B1 (en) 2016-06-22
JP6005051B2 (ja) 2016-10-12
CN103384827A (zh) 2013-11-06
MX2013005762A (es) 2013-08-12
HUE030005T2 (en) 2017-04-28
EP2643698A1 (en) 2013-10-02
KR20130119453A (ko) 2013-10-31
US9389235B2 (en) 2016-07-12
WO2012069462A1 (en) 2012-05-31
CA2818738A1 (en) 2012-05-31
CN103384827B (zh) 2016-06-08
JP2014500493A (ja) 2014-01-09
GB201021289D0 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
PL2643698T3 (pl) Biomarkery do przewidywania skuteczności immunoterapii raka
SMT201600135B (it) Nuovi inibitori della s-nitrosoglutatione riduttasi
SMT201700109B (it) Inibitori di istone demetilasi
EP2758080A4 (en) ANTICANCER IMMUNOTHERAPY
EP2536854A4 (en) PERSONALIZED TUMOR BIOMARKERS
EP2625292A4 (en) KREBSBIOMARKER
EP2596467A4 (en) Credit risk mining
FR2966037B3 (fr) Ensemble balai-eponge
IL252163A0 (en) Lung cancer biomarkers and uses thereof
PL3296319T3 (pl) Sposoby leczenia nowotworu jelita grubego
ES2638522T8 (es) Procedimientos para detectar cáncer
IL221719A (en) Biomarkers for theranostics
LT3444512T (lt) Vamzdžių konstrukcija
IL229319A0 (en) Biomarkers for lung cancer
LT3284754T (lt) Antikūnai prieš cd38
SMT201600370B (it) Complessi chelati di oligonucleotidi
IL220084A (en) Tumor tissue based biomarkers for bevacizumab combination therapies
BR112013011752A2 (pt) curtimento não metálico
IL228636A0 (en) Biomarkers for predicting sensitivity to cancer treatments
EP2775844A4 (en) BIOMARKER FOR THE RESPONSE TO NAE INHIBITORS
ZA201703026B (en) Biomarkers for the prediction of incident cancer
EP2638355A4 (en) TOOL REVOLVER ARRANGEMENT
BR112012019494A2 (pt) dispositivo elétrico
BR112013000371A2 (pt) invólucro
EP2558859A4 (en) MICRO ARRAYS